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Introduction: Platelet-derived growth factor receptor (PDGFR) is
expressed in lung cancer and is involved in angiogenesis. Preclinical
models demonstrated that imatinib (Im) regulates angiogenesis
through PDGFR inhibition and enhances efficacy of chemotherapy.
Hypothesis: We hypothesized that Im plus docetaxel (D) would have
a synergistic effect detectable by an increase in response rate in
patients with recurrent non-small cell lung cancer (NSCLC).
Methods: A phase II trial to evaluate Im in combination with D in
patients with recurrent NSCLC was conducted. The primary end
point was response rate, using a Simon two-stage design. Eligible
patients had measurable disease and no more than two chemother-
apy regimens. D was given at 30 mg/m2/wk intravenously 3 every
4 weeks and oral Im at 600 mg daily for four cycles. Patients
required two cycles to be evaluable for response. Nonprogressors
after four cycles continued with Im maintenance until progression or
for a total of 12 months.
Results: Twenty-three patients were enrolled in the first stage.
Toxicity was mainly nonhematologic. We observed one partial
response (5.5%), four stable disease (22.2%), and 13 progressed
(72.2%). Median time to progression was 1.9 months, and median
overall survival was 6.1 months. Two patients who went on Im
maintenance had time to progression of 7.78 months and 15.8
months.
Conclusion: Im in combination with D did not achieve its primary
objective of improving response rate in patients with recurrent
NSCLC. An increased understanding of the complex PDGFR path-
way in lung cancer and alternative strategies to inhibit it are needed.
Key Words: Imatinib, Docetaxel, Platelet-derived growth factor
receptor, Recurrent Lung cancer.
(J Thorac Oncol. 2011;6: 372–377)
Advanced non-small cell lung cancer (NSCLC) is nearlyalways fatal. First-line therapy using platinum doublets
demonstrated a time of progression of only 3 to 4 months and
30% 1-year survival rate.1 The use of second-line treatment
after failure of a platinum-based doublet has become routine
for patients with advanced NSCLC, producing a modest
increase in survival. Docetaxel (D), the first agent approved
for patients with relapsed NSCLC with good performance
status (PS), showed an improved median survival and quality
of life compared with best supportive care.2 Compared with
ifosfamide or vinorelbine, it showed a superior response rate,
1-year survival rate, and a progression-free survival (PFS) of
26 weeks.3 Nevertheless, this benefit was incremental with a
response rate of 7 to 8% and median survival times of 6 to 7
months. Clearly, there is a need to develop more active
treatment in both the first and second-line setting to further
improve survival of these patients.
A novel targeted pathway involves platelet-derived
growth factors (PDGFs) that comprised four polypeptide
chains (PDGF-A, B, C, and D) encoded by four different
genes that result in five dimeric isoforms (PDGF-AA, -BB,
-CC, -DD, and -AB). These isoforms bind to one of three
PDGF receptors (PDGFR-, PDGFR-, or PDGFR-)
resulting in the activation of a downstream signaling cascade
that promotes cellular proliferation, migration, and survival.4
The PDGF pathway is also involved in angiogenesis by
inducing vascular endothelial growth factor (VEGF),5 recruit-
ing pericytes, and stimulating vascular smooth muscle cells.6
The four PDGF chains also contain a domain similar to
VEGF, named the PDGF/VEGF homology domain.7
Both PDGF and its receptor (PDGFR) have been de-
tected in lung cancer cells but not in normal cells. PDGF is
expressed in lung cancer, and it is an independent poor
prognostic marker.8 Two studies demonstrated PDGFR-
expression in lung cancer, and PDGFR- was detected in
stromal tissue only.9,10 Another study also confirmed worse
prognosis associated with PDGF and PDGFR expression.11
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The presence of activated PDGFR- is predictive of response
to PDGFR inhibitor.12
Inhibition of PDGFRs in stromal cells leads to de-
creased interstitial fluid pressure and increased capillary-to-
interstitium transport of small molecule, which could poten-
tially result in the delivery of more chemotherapy to the
tumor site.13 This hypothesis is currently being tested through
a phase II clinical trial of paclitaxel with Im in patients with
NSCLC older than 70 years, clinical trial identification num-
ber NCT00408460. Thus, targeting the PDGF pathway is a
reasonable approach and an attractive strategy given that
PDGF inhibitors are readily available for evaluation.
Imatinib (Im) mesylate is primarily known as a protein-
tyrosine kinase inhibitor of Bcr-Abl used in the treatment of
chronic myelogenous leukemia. Im is also an inhibitor of
stem cell factor CD117 receptor, known as C-KIT. Im inhib-
its PDGF and stem cell factor-mediated cellular events of
cellular proliferation, gene expression, and cell migration. In
preclinical studies, it enhanced the effect of chemotherapy
agents such as 5 fluorouracil, paclitaxel, and cisplatin in lung
cancer cells.14,15 Uehara et al.16 demonstrated that the Im and
taxane combination had superior efficacy compared with
either agent administered individually in a prostate cancer
bone metastasis model. A phase I trial established the dose of
D at 30 mg/m2 weekly in combination with Im at 600 mg
daily. They observed clinical activity with PSA decline in 14
patients (67%). These results suggest potential synergistic
interaction between D and inhibition of PDGFR using Im.17
On the basis of these observations, we initiated a phase
II study to assess the potential role of PDGFR inhibition,
using Im in combination with D (ImD), in patients with
recurrent NSCLC. Our primary objective was to determine
the response rate of the combination. Secondary objectives
included determination of the expression of PDGF-R, phos-
phorylated PDGF-R, and C-KIT in the available lung cancer
tissue. We also analyzed the toxicity profile, time to progres-
sion (TTP), and overall survival of patients treated with this
combination.
PATIENTS AND METHODS
The study was registered under clinical trials ID:
NCT00222144. Adult patients with a histologic or cytologic
diagnosis of NSCLC, documented recurrent or progressive
disease by radiographic and/or clinical examination, and an
Eastern Cooperative Oncology Group PS 0 to 1 were eligible.
Subjects could have a maximum of two prior chemotherapy
regimens excluding D, received prior EGFR therapy, or have
clinically stable brain metastatic disease. Bidimensional mea-
surable disease, adequate hematological, renal and hepatic
function, and a forced expiratory volume-1 more than 800 ml
were required. The forced expiratory volume-1 was an entry
criterion to eliminate possible poor prognosis associated with
patients with severe chronic obstructive pulmonary disease.
Tumor samples for immunohistochemistry (IHC) analysis for
PDGFR- and , their phosphorylated form, and C-KIT were
requested but not mandated. The protocol was approved by
Institutional Review Boards at the University of Kansas
Medical Center and the Kansas City VA Medical Center. All
patients were consented and informed of the investigational
nature of the trial before initiation of the study procedures.
Study Treatment
D was given at 30 mg/m2 IV weekly for 3 weeks and 1
week off. Patients received premedication with dexametha-
sone 4 mg orally for three doses beginning on the evening
before D. Im was orally administered at 600 mg daily starting
on day 1 of D treatment and continued while the patient was
receiving D.
Patients had tumor assessment by radiographic exami-
nation every two cycles. After four cycles of ImD, patients
with response or stable disease continued Im alone as main-
tenance until disease progression or for a total of 12 months.
This study used the National Cancer Institute common tox-
icity criteria version 3.0 for toxicity and adverse event re-
porting. D was dose reduced if there were grade 3 or 4
hematologic toxicity. Im was dose reduced if there was grade
3 or 4 toxicity. Im also reduced if there was recurrence of
grade 2 toxicity. Use of diuretics was allowed to treat edema
related to D or Im.
Study Evaluation and Follow-Up
Prestudy evaluation included a complete medical his-
tory and physical examination including PS, laboratory anal-
ysis, pulmonary function tests, electrocardiogram, and base-
line computed tomography scans of the measurable disease
site, including chest and abdomen, 28 days before study
entry. Response assessment occurred after every two cycles
of ImD. Patients had complete blood count, chemistries,
history, physical, and toxicity evaluation at the beginning of
each cycle of ImD. Patients on the Im maintenance phase had
a history and physical examinations, blood work, tumor
assessment by radiographic examination, and toxicity evalu-
ation every 2 months for total of 12 months or until disease
progression. Patients could be removed from the study if
unable to tolerate therapy due unacceptable toxicity, disease
progression, development of an intercurrent, non–cancer-
related illness that prevented study continuation, or patient
refusal.
Immunohistochemical Studies
IHC stains for PDGFR-, PDGFR-, their respective
phosphorylated form and C-KIT were performed on 4-m
thick sections cut from archived formalin-fixed paraffin em-
bedded tissue blocks, when available. Commercially avail-
able antibodies against these markers were used per manu-
facturer’s protocols, and staining was performed on a Dako
Autostainer (Dako, Carpinteria, CA). Epitope retrieval using
microwave heat or steam pretreatment was performed as
required. Appropriate positive and negative tissue controls
were performed with each run. All slides were evaluated by
one pathologist who had no knowledge of the patient’s
clinical status. Cellular staining intensity was graded for each
marker on a score from 0 to 3. Staining characteristics was
documented according to standard criteria, using a scale of 0
to 1, 2, 3, according to the intensity of staining.
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Statistical Analysis
The primary objective was to evaluate the response rate
of ImD in patients with recurrent NSCLC. Patients had to
complete two cycles to be evaluable for response based on
RECIST criteria. The secondary objectives were to determine
the toxicity, PFS, overall survival, and expression of
PDGF-R, phosphorylated PDGF-R, and C-KIT in the original
tissue and correlate with response.
The treatment would be of interest if the proportion of
patients with a favorable response was at least 35%, and it
would be of no interest if the overall response was 15%.
Thirty-two patients would be needed to test the null hypoth-
esis: p  0.15 and against the alternative hypothesis: p 
0.35 with 10% significance and 90% power. The rationale for
this is given by Rogatko and Litwin.18 The type I and II errors
are 10%. We used a two-stage design under constraints to
minimize the maximum sample size. The early stopping point
was 20 patients. If three or fewer patients with a response
were observed with 20 patients accrued, then the null hypoth-
esis would be accepted, and the trial would be terminated.
The probability of early stopping under the null hypothesis
was 0.648 and under the alternative was 0.044. If the trial
progressed until 32 patients were evaluated, it would require
eight or more responding patients to reject the null hypothe-
sis. Patients who did not receive two full cycles and not
evaluable for response were replaced.
RESULTS
The study enrolled a total of 23 patients from January
2005 to December 2007. Patient characteristics are summa-
rized in Table 1. The median age was 70 years with a range
of 54 to 83 years. The majority of patients were men, white
with PS of 1. The predominant histologic classification was
non-small cell carcinoma, not otherwise specified. Twenty-
two patients received a front-line platinum-based doublet,
and one patient received erlotinib. Four patients had second-
line therapy, and one patient had third-line therapy with
erlotinib. Two patients had brain metastasis.
Twenty-three patients were enrolled, and 18 were
evaluable for response. Five were not evaluable because they
did not complete the required two cycles of therapy. One
patient achieved a partial response (5.5%), four patients had
stable disease, and 13 patients had progressive disease
(72.2%). The disease control rate (partial response  stable
disease) was 27.7%. The median TTP was 1.9 months (Figure
1), and the median overall survival was 6.1 months (Figure
2). Two patients who completed four cycles of therapy went
on to maintenance therapy and had prolonged disease control
with TTP of 7.78 months and 15.8 months. The study was
stopped at 18 evaluable patients because two additional
patients would not have altered study termination per the
design criteria.
Toxicity
All 23 patients were evaluable for toxicity. A total of 39
cycles of ImD were administered. There was no grade 3 or 4
hematological toxicity. Adverse events possibly related to
study treatment are described in Table 2 and included grade
3 dyspnea (two); grade 3 chest pain (one); grade 4 non-ST
myocardial infarction (one); grade 3 hypokalemia (one);
TABLE 1. Patient Characteristics
Patient Characteristics N  23










Third-line therapy with erlotinib 1
Eighteen had ImD as second-line therapy, four as third line, and one as fourth line.
ImD, Im in combination with D; PS, performance status.
FIGURE 1. Time to progression.
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grade 3 neurologic syncope (two). One possible treatment-
related death occurred. We did observe seven patients who
required Im dose reduction from 600 to 400 mg/d (three due
to diarrhea, two due to cough, one due to increase liver
function tests, and one due to nausea and vomiting).
The majority of patients (n  16) discontinued the
study due to disease progression, and seven patients discon-
tinued treatment due to other reasons (one withdrew consent,
one due to noncompliance, one due to loss to follow-up, one
due to patient decision, one due to myocardial infarction
before initiation of therapy, one due to MI during treatment,
and death in one).
Immunohistochemical Results
We obtained tumor specimens from 15 patients and
performed IHC analysis. The results are described in Table 3.
More than 50% of the cases had staining in 75 to 100% of
tumor cells (nine cases), and in the rest of the cases, there was
at least expression in 50% in tumor cells (five cases) with
only one case showing expression in 30% of tumor cells and
one with no staining. We did not detect significant expression
in the stroma. The majority of tumors had low biomarker
expression (1) across all the markers tested. Significant
expression of 2 to 3 was seen in four tumors (two adeno-
carcinoma and one squamous cell, and one not specified)
(27%) for PDGF- expression, and seven tumors (four ade-
nocarcinoma, two squamous, and one not specified) (47%)
had phosphorylated PDGFR-. There was one case with 3
C-KIT expression. The 2 to 3 IHC results of the four
patients with stable disease were as follows: one patient had
2 phosphorylated PDGFR-; one patient had 3 phosphor-
ylated PDGFR-; and two patients did not have specimen
available. The patient with the partial response had 1
PDGFR- in 100% of cells. A representative picture of tumor
sample is in Figure 3.
DISCUSSION
In this small pilot study, the addition of Im to a weekly
schedule of D did not meet the primary objective of an improve-
ment in response rate in patients with relapsed NSCLC. A
similar study conducted by White et al. also did not show
significant activity in patients with recurrent NSCLC, with only
one objective response in 10 patients. That study used the same
dose of Im and D although it allowed prior D treatment. Three
patients achieved stable disease, but all were of short duration.19
Another phase II study from MD Anderson, clinical trials
identification NCT01083589, using Im with D 60 mg/m2 every
3 weeks in previously treated NSCLC, is currently ongoing.
Studies with ImD have produced mixed results in other tumor
types. ImD combination in platinum-resistant epithelial ovarian
cancer showed a response rate of 21.7%. IHC expression of
PDGFR, C-KIT, and PDGFR-  in tumor specimen did not
predict response or PFS.20 In metastatic breast cancer, ImD
produced a response rate of 12%, median PFS of 3 months, and
overall survival of 10 months in 18 evaluable patients.21 In the
FIGURE 2. Overall survival.
TABLE 2. Grade 3/4 Adverse Event Possibly Related to
Study Treatment
Adverse Events N Grade
Dyspnea 2 3
Chest pain 1 3
Non-ST MI with elevated troponin 1 4
Hypokalemia 1 3
Syncope 2 3
One death possibly due to study treatment.
TABLE 3. Immunohistochemistry Results, N  15
PGDFR  pPDGFR  PDGFR  pPDGFR  C-KIT
0–1 11a 8 14 15 13
2 2 1b 1 — 1
3 2 6b — — 1
a Partial response.
b Stable disease.
PGDFR, platelet-derived growth factor receptor; pPGDFR, phosphorylated platelet-
derived growth factor receptor.
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neoadjuvant setting of breast cancer, ImD yielded a response
rate of 25%.22
There are several possible explanations for our negative
outcome. We postulated that the mechanism of action of Im
was predominantly angiogenesis inhibition through PDGF
pathway blockade. In preclinical models, Im was a modestly
potent inhibitor of PDGFR, but more potent inhibitors are
available. Moreover, PDGF may not be a dominant angio-
genesis promoter in relapsed NSCLC and requires coinhibi-
tion with other factors such as VEGF. Laboratory studies
showed close interaction between the VEGF and PDGF
systems with coactivation of the PDGF system when VEGF
receptor is inhibited.23,24 These studies support a combination
strategy of VEGF and PDGFR- inhibition with multiangio-
kinase inhibitors or dual agents. Angiokinases with multiple
pathway inhibition, such as sorafenib, are currently in clinical
trials. A phase II trial of sorafenib in relapsed NSCLC did not
induce responses but produced stable disease in 59% of pa-
tients.25 The University of Washington is conducting a pilot trial
of bevacizumab and Im maintenance after a platinum doublet
plus bevacizumab, clinical trials ID NCT00425646. This is an
attractive strategy given our observation of prolonged disease
stabilization (7.8 and 15.8 months) in two patients who went on
to receive Im maintenance. Another possibility is to add a
PDGFR inhibitor at the time of recurrence after bevacizumab
maintenance or in first-line setting in conjunction with a VEGF
receptor inhibitor.
D was given on a weekly basis as a means to enhance
antiangiogenesis. D, similar to many chemotherapy agents, is
known to possess antiangiogenic properties that are maxi-
mized when the drug is given on a more continuous basis.26
Although there is controversy surrounding the efficacy of
weekly D as being inferior to the every 3-week regimen, a
meta-analysis comparing these two schedules did not show a
difference in response rate or TTP or overall survival.27
Therefore, it is unlikely that the schedule of D administration
was responsible for the lack of antitumor activity seen in this
study. A drug-drug interaction between Im and D is another
possible explanation for the low response rate observed. D is
a substrate for the CYP3A3/4 system. Im is also known to
interact with the same isoenzyme and, therefore, could po-
tentially lead to increased metabolism of D. Unfortunately,
we did not design the study to look for pharmacological
interaction between these two drugs.
The IHC data in a limited patient sample demonstrated
that there is expression of PDGFR- but no significant expres-
sion of PDGFR- or C-KIT. This may explain the lack of
significant activity of Im in our study, although two patients with
stable disease had expression of PDGFR and its phosphory-
lated form and both had prolonged TTP of 7.8 and 15.8 months.
In retrospect, our selection of response rate and the magnitude of
the benefit required to pursue this combination was overly
ambitious. Perhaps, future studies using Im should be done in
preselected patients with specific clinical characteristics (i.e., PS
0–1, absence of brain metastatic disease, and limited to second-
line therapy) and positive expression of PDGFR or its phosphor-
ylated form, looking at improvement of TTP at 6 months or
1-year overall survival as primary objective. The presence of
C-KIT mutation predicts the activity of Im in gastrointestinal
stromal tumors. Future studies in NSCLC should also perform
analysis of C-KIT mutation.
The study regimen was well tolerated. We did not
observe severe hematologic toxicities. The grade 3 nonhema-
tological events were rare and atypical. Although classified as
possibly related to study treatment, the events are commonly
seen in this patient population.
CONCLUSIONS
PDGFR inhibition using ImD did not achieve the pri-
mary end point of improvement in response rate. This could
be due to insufficient inhibition of angiogenesis through the
PDGFR system by Im or combination of ImD; possible
negative pharmacological interaction between D and Im with
reduction in drug level; and low levels of expression of
PDGFR in the patient population studied. A better under-
standing of the PDGFR pathway in lung cancer is needed to
provide more rational therapeutic approaches. Inhibition of
PDGFR using Im is potentially a new strategy in the treat-
ment of cancer and deserves further investigation by combin-
ing it with another antiangiogenesis drug such as bevaci-
zumab or other multitarget angiogenesis kinases, preferably
in a group of patients with positive PDGFR expression and
specific clinical characteristics. Correlation with C-KIT mu-
tation should also be investigated. We would also suggest
using PFS at 6 months as a primary end point in future
clinical studies using these agents in recurrent NSCLC.
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